Sildenafil Dosing for Erectile Dysfunction
The recommended starting dose of sildenafil for erectile dysfunction is 50 mg, taken approximately 1 hour before sexual activity, with titration to 100 mg if inadequate or reduction to 25 mg based on tolerability. 1
Standard Dosing Protocol
- Start with 50 mg taken 1 hour before anticipated sexual activity, not more than once daily 1
- If 50 mg is inadequate after an adequate trial, increase to 100 mg (maximum dose) 1
- If side effects are problematic, reduce to 25 mg 1
- Sexual stimulation is mandatory for effectiveness—the medication will not work without it 1
Dose-Response Relationship
- Sildenafil demonstrates dose-dependent improvement in erectile function, with 50 mg being more effective than 25 mg 2, 1
- The 100 mg dose shows additional benefit over 50 mg, particularly in reducing anxiety about the next intercourse attempt (56% vs 39% felt no anxiety) and improving treatment satisfaction 3
- An adequate trial requires at least 5 separate attempts at maximum tolerated dose before declaring treatment failure 1
Special Populations Requiring Dose Adjustment
Reduce starting dose to 25 mg in the following situations: 1
- Severe renal impairment (CrCl <30 mL/min): Sildenafil clearance is reduced by approximately 50%, resulting in doubling of AUC and Cmax 4
- Severe hepatic impairment (Child-Pugh class C): Sildenafil clearance is reduced, with 84% increase in AUC and 47% increase in Cmax 4
- Concurrent CYP3A4 inhibitors: Including ritonavir, saquinavir, ketoconazole, erythromycin, or cimetidine, which reduce sildenafil clearance by approximately 30% 1, 4
- Age >65 years: Elderly patients have 84% higher plasma concentrations due to reduced clearance 4
Note: Mild to moderate renal impairment (CrCl 30-80 mL/min) does not require dose adjustment 4
Critical Safety Contraindications
- Absolute contraindication with any form of nitrate use (organic nitrates, glyceryl trinitrate, isosorbide dinitrate) due to potentially fatal hypotension 1
- If emergency nitrate administration is needed, wait at least 24 hours after sildenafil use under close medical supervision 1
- High-risk cardiovascular conditions requiring cardiac stabilization before treatment include: unstable angina, uncontrolled hypertension, recent MI or stroke (within 2 weeks), severe heart failure (NYHA class II or higher), and high-risk arrhythmias 1
Pre-Treatment Cardiovascular Assessment
- Verify the patient can walk 1 mile in 20 minutes or climb 2 flights of stairs without symptoms 2
- If unable to perform this level of activity, refer to cardiology before prescribing 2
- Explicitly ask about all forms of nitrate use, including recreational use 2
Common Pitfalls Leading to Treatment Failure
Many apparent failures result from modifiable factors rather than true medication ineffectiveness: 1
- Lack of sexual stimulation: The medication requires arousal to work 1
- Taking with large meals: High-fat meals delay absorption by 60 minutes and reduce Cmax by 29% 4
- Inadequate number of attempts: Need at least 5 attempts at maximum dose before declaring failure 1
- Heavy alcohol use: Impairs erectile function and should be addressed 2
- Improper timing: Take 1 hour before sexual activity (peak plasma levels occur at 30-120 minutes, median 60 minutes) 4
Expected Efficacy
- Success rate of 69% for successful sexual intercourse attempts vs 35.5% with placebo 1
- 73-88% improvement in erections vs 26-32% with placebo 1
- Efficacy maintained across various etiologies including diabetes (56% improvement), spinal cord injury (75% improvement), and cardiovascular disease 5, 6
- Men with diabetes and post-prostatectomy patients may respond less robustly due to more severe baseline ED 1
Combination Therapy Considerations
- For patients with low testosterone (<300 ng/dL), adding testosterone replacement therapy to sildenafil is more effective than either alone 1
- Before declaring treatment failure, evaluate and correct hormonal abnormalities 2
Common Adverse Effects
- Most frequent: headache, flushing, dyspepsia, nasal congestion, and abnormal vision 1
- These are typically transient and mild-to-moderate 1
- No increase in adverse events with 100 mg vs 50 mg in clinical trials 3
Ongoing Management
- Periodic follow-up should verify cardiovascular health stability, assess new medications (particularly CYP3A4 inhibitors), evaluate treatment effectiveness, and monitor side effects 1
- If 100 mg fails after an adequate trial, consider switching to a different PDE5 inhibitor (tadalafil or vardenafil) rather than declaring all oral therapy ineffective 1